"Oxazolidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.
| Descriptor ID |
D023303
|
| MeSH Number(s) |
D03.383.129.462.600
|
| Concept/Terms |
Oxazolidin-2-one- Oxazolidin-2-one
- Oxazolidin 2 one
- 2-oxazolidinone
- 2 oxazolidinone
- 2-Oxazolidone
- 2 Oxazolidone
- 1,3-Oxazolidin-2-one
- 1,3 Oxazolidin 2 one
- 1,3-Oxazolidine-2-one
- 1,3 Oxazolidine 2 one
|
Below are MeSH descriptors whose meaning is more general than "Oxazolidinones".
Below are MeSH descriptors whose meaning is more specific than "Oxazolidinones".
This graph shows the total number of publications written about "Oxazolidinones" by people in this website by year, and whether "Oxazolidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxazolidinones" by people in Profiles.
-
A case of lactic acidosis induced by linezolid. Nat Rev Nephrol. 2010 Apr; 6(4):236-42.
-
Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010 Feb; 19(2):231-7.
-
Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Dispos. 2010 Mar; 38(3):459-73.
-
Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit. Surg Infect (Larchmt). 2008 Aug; 9(4):423-31.
-
Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2004 Jan; 48(1):281-4.